MEK inhibition induces MYOG and remodels super-enhancers in RAS-driven rhabdomyosarcoma

@article{Yohe2018MEKII,
  title={MEK inhibition induces MYOG and remodels super-enhancers in RAS-driven rhabdomyosarcoma},
  author={Marielle E. Yohe and Berkley E. Gryder and Jack F. Shern and Young K. Song and Hsien-Chao Chou and Sivasish Sindiri and Arnulfo Mendoza and Rajesh Patidar and Xiaohu Zhang and Rajarashi Guha and Donna O. Butcher and Kristine A. Isanogle and Christina M. Robinson and Xiaoling Luo and Jinqui-Qiu Chen and Ashley Walton and Parirokh Awasthi and E. Edmondson and Simone Difilippantonio and Jun S. Wei and Keji Zhao and Marc Ferrer and Craig J. Thomas and Javed Khan},
  journal={Science Translational Medicine},
  year={2018},
  volume={10}
}
MEK inhibition decreases cell viability and induces differentiation in RAS-driven rhabdomyosarcoma via an epigenetic mechanism. Muscling in on RAS Rhabdomyosarcomas occur when skeletal muscle precursors fail to differentiate. These tumors often display mutated RAS, although the mechanism through which RAS promotes tumor formation has remained unclear. Yohe et al. discovered that RAS blocks myogenesis in fusion-negative rhabdomyosarcoma (FN-RMS) by inducing epigenetic changes via the MAP kinase… 
CASZ1 induces skeletal muscle and rhabdomyosarcoma differentiation through a feed-forward loop with MYOD and MYOG
TLDR
CASZ1 directly regulates these myogenic factors and the loss of CASZ1 is due to RAS-MEK signaling in ERMS, impairs ERMS differentiation, contributing to RMS tumorigenesis.
Interaction between SNAI2 and MYOD enhances oncogenesis and suppresses differentiation in Fusion Negative Rhabdomyosarcoma
TLDR
It is reported that SNAI2 is highly expressed in FN-RMS, is oncogenic, blocks myogenic differentiation, and promotes growth, and an interplay between S NAI2, MYOD, and RAS prevents myogenic differentiate and promotes tumorigenesis.
Sensitization to Ionizing Radiation by MEK inhibition is Dependent on SNAI2 in Fusion-negative Rhabdomyosarcoma
TLDR
The findings demonstrate that the combination of MEK inhibition and IR results in robust differentiation and apoptosis, due to the reduction of SNAI2, which leads to extended EFS in FN-RMS.
BAF complexes drive proliferation and block myogenic differentiation in fusion-positive rhabdomyosarcoma
TLDR
It is concluded that inhibition of BRG1 overcomes the differentiation blockade of FP-RMS cells and may provide a therapeutic strategy for this lethal childhood tumor.
Selective Targeting of Myoblast Fusogenic Signaling and Differentiation-Arrest Antagonizes Rhabdomyosarcoma Cells.
TLDR
It is demonstrated that Akt inhibition antagonizes RMS - including RMS resistant to EGFR inhibition - and sustained activity of the Akt1 isoform preferentially blocks rhabdomyoblast differentiation potential in cell culture and in vivo, pointing towards selective targeting of fusion- and differentiation-arrest via Akt as a broad RMS therapeutic vulnerability.
Rigosertib Induces Mitotic Arrest and Apoptosis in RAS-Mutated Rhabdomyosarcoma and Neuroblastoma
TLDR
It is shown that the small-molecule rigosertib inhibits the growth of RMS and NB cell lines by arresting cells in mitosis, which leads to cell death, and the combination of rigoertib and the MEK inhibitor trametinib synergistically inhibits the Growth of an RMS cell line, suggesting a new avenue for combination therapy.
Context-dependent modulation of aggressiveness of pediatric tumors by individual oncogenic RAS isoforms
TLDR
Together, all three oncRAS mutations seem to be advantageous for ERMS cell lines despite inhibition of HH signaling and isoform-specific modulation of stem cell markers, and this window may be different for individual on cRAS isoforms, at least in the mouse.
KDM3A/Ets1/MCAM axis promotes growth and metastatic properties in Rhabdomyosarcoma
TLDR
It is shown that the epigenetic regulator KDM3A, a member of the Jumonji-domain histone demethylase (JHDM) family, is overexpressed, potently promotes colony formation and transendothelial invasion, and activates the expression of genes involved in cell growth, migration and metastasis, in both FN-R MS and FP-RMS.
The RNA helicase DDX5 promotes alveolar rhabdomyosarcoma growth and survival
TLDR
The findings identify a novel survival-promoting loop in FP-ARMS and highlight DDX5 as potential therapeutic target to arrest rhabdomyosarcoma growth.
...
...

References

SHOWING 1-10 OF 99 REFERENCES
Silencing of SPRY1 triggers complete regression of rhabdomyosarcoma tumors carrying a mutated RAS gene.
TLDR
It is argued that SPRY1 inhibition can offer a therapeutic strategy to treat childhood rhabdomyosarcoma and possibly other tumors carrying oncogenic RAS mutations.
Pharmacological inhibition of EZH2 as a promising differentiation therapy in embryonal RMS
TLDR
These results provide evidence that EZH2 function can be counteracted by pharmacological inhibition in embryonal RMS blocking proliferation even in a pro-proliferative context and suggest that this approach could be exploited as a differentiation therapy in adjuvant therapeutic intervention for embryonic RMS.
MEK/ERK inhibitor U0126 affects in vitro and in vivo growth of embryonal rhabdomyosarcoma
TLDR
Results indicate that MEK/ERK inhibition affects growth and angiogenic signals in tumor, and suggests that MeK inhibitors may be investigated for a signal transduction-based targeting of the c-Myc as a therapeutic strategy in ERMS.
Effects of RAS on the genesis of embryonal rhabdomyosarcoma.
TLDR
A zebrafish model of RAS-induced ERMS is created, in which animals develop externally visible tumors by 10 d of life, and it is proposed that the zebra fish RMS cancer stem cell shares similar self-renewal programs as those found in activated satellite cells.
Oncogenic NRAS, required for pathogenesis of embryonic rhabdomyosarcoma, relies upon the HMGA2-IGF2BP2 pathway.
TLDR
The identification of the minor groove DNA-binding factor high mobility group AT-hook 2 (HMGA2) as a driver of ERMS development implicate the HMGA2-IGFBP2-NRAS signaling pathway as a critical oncogenic driver in ERMS.
PAX3-FOXO1 Establishes Myogenic Super Enhancers and Confers BET Bromodomain Vulnerability.
TLDR
It is found that PAX3-FOXO1 establishes a myoblastic super enhancer landscape and creates a profound subtype-unique dependence on BET bromodomains, providing a mechanistic rationale for exploring BET inhibitors for patients bearing PAX-fusion rhabdomyosarcoma.
Activated Raf inhibits avian myogenesis through a MAPK-dependent mechanism
TLDR
The results indicate that the Raf/MEK/MAPK axis is intact in chick myoblasts and that persistent activation of this signaling cascade is inhibitory to myogenesis.
Cooperation of oncogenic K-ras and p53 deficiency in pleomorphic rhabdomyosarcoma development in adult mice
TLDR
Cooperation of oncogenic K-ras and p53 deficiency resulted in the development of pleomorphic RMS in adult mice, providing a useful mouse model for further detailed studies.
A recurrent neomorphic mutation in MYOD1 defines a clinically aggressive subset of embryonal rhabdomyosarcoma associated with PI3K-AKT pathway mutations
TLDR
This work reports the discovery of a recurrent somatic mutation encoding p.Leu122Arg in the myogenic transcription factor MYOD1 in a distinct subset of ERMS tumors with poor outcomes that also often contain mutations altering PI3K-AKT pathway components.
Dominant role of oncogene dosage and absence of tumor suppressor activity in Nras-driven hematopoietic transformation.
TLDR
It is shown that increased Nras(G12D) gene dosage, but not inactivation of WT Nras, underlies the aggressive in vivo behavior of Nras’ hematopoietic cells and support reconsidering the proposed tumor suppressor activity of WT Ras in other cancers.
...
...